CYAD-101

DRUG2 trials

Sponsors

Celyad Oncology SA

Conditions

Unresectable Metastatic Colorectal Cancer

Phase 1

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

RecruitingNCT03692429

Celyad Oncology SAUnresectable Metastatic Colorectal Cancer

Start: 2018-11-28End: 2036-02-17Target: 49Updated: 2020-11-20

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

RecruitingNCT04991948

Celyad Oncology SAUnresectable Metastatic Colorectal Cancer

Start: 2021-11-22End: 2038-05-25Target: 34Updated: 2022-03-09

Related Papers

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy

Journal of Immunotherapy2022-02-2227 citations

KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients.

Journal of Clinical Oncology2022-01-199 citations

407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients

Regular and Young Investigator Award Abstracts2021-11-01

Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.

Journal of Clinical Oncology2021-01-2039 citations

CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.

Journal of Clinical Oncology2020-05-207 citations